Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of “Moderate Buy” by Analysts

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $21.00.

A number of brokerages have weighed in on PHAT. Guggenheim reaffirmed a “buy” rating and issued a $20.00 target price on shares of Phathom Pharmaceuticals in a report on Thursday, October 30th. Barclays assumed coverage on Phathom Pharmaceuticals in a research report on Monday, December 8th. They set an “equal weight” rating and a $16.00 price objective for the company. Craig Hallum reiterated a “buy” rating and issued a $22.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday, October 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Thursday, January 22nd. Finally, Raymond James Financial began coverage on Phathom Pharmaceuticals in a report on Thursday, December 11th. They set a “strong-buy” rating and a $28.00 price objective on the stock.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Large investors have recently modified their holdings of the company. Jones Financial Companies Lllp grew its holdings in Phathom Pharmaceuticals by 442.6% in the third quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock worth $30,000 after purchasing an additional 2,058 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Phathom Pharmaceuticals in the 2nd quarter valued at about $30,000. Ameritas Investment Partners Inc. grew its stake in shares of Phathom Pharmaceuticals by 39.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company’s stock valued at $41,000 after buying an additional 1,216 shares during the period. BNP Paribas Financial Markets increased its position in Phathom Pharmaceuticals by 71.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company’s stock valued at $49,000 after buying an additional 2,122 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Phathom Pharmaceuticals by 58.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company’s stock worth $55,000 after buying an additional 2,102 shares during the period. 99.01% of the stock is currently owned by institutional investors and hedge funds.

Phathom Pharmaceuticals Trading Up 1.0%

NASDAQ PHAT opened at $13.81 on Thursday. The company has a market cap of $986.31 million, a price-to-earnings ratio of -3.62 and a beta of 0.48. The company has a 50 day moving average of $15.32 and a 200-day moving average of $13.05. Phathom Pharmaceuticals has a 1-year low of $2.21 and a 1-year high of $18.31.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical?stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium?competitive acid blocker (P-CAB) licensed for use in the United States.